Invivyd, Inc. (IVVD)

NASDAQ: IVVD · IEX Real-Time Price · USD
2.32
+0.11 (4.98%)
At close: Dec 2, 2022 4:00 PM
2.25
-0.07 (-3.02%)
Pre-market: Dec 5, 2022 5:45 AM EST
4.98%
Market Cap 240.85M
Revenue (ttm) n/a
Net Income (ttm) -279.79M
Shares Out 108.42M
EPS (ttm) -0.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 180,884
Open 2.15
Previous Close 2.21
Day's Range 2.12 - 2.33
52-Week Range 2.08 - 47.37
Beta n/a
Analysts Sell
Price Target 3.91 (+68.5%)
Earnings Date Nov 10, 2022

About IVVD

Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. It also has discovery stage candidates for the prevention of seasonal influenza. Invivyd, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of propri... [Read more]

Industry Biotechnology
IPO Date Aug 6, 2021
Employees 101
Stock Exchange NASDAQ
Ticker Symbol IVVD
Full Company Profile

Analyst Forecast

According to 9 analysts, the average rating for IVVD stock is "Sell." The 12-month stock price forecast is 3.91, which is an increase of 68.53% from the latest price.

Price Target
$3.91
(68.53% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseas...

-Broad partnership will strengthen Invivyd's development platform and organizational capabilities towards acceleration of NVD200 clinical program and future engineered antibodies for COVID-19 and beyond-

2 weeks ago - GlobeNewsWire

Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights

Novel monoclonal antibody combination candidate (NVD200) on track to advance into clinical trials in Q1 2023

3 weeks ago - GlobeNewsWire

Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference

WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today ...

3 weeks ago - GlobeNewsWire

Invivyd to Host Conference Call on November 10 to Discuss Third Quarter 2022 Financial Results and Recent Business Hi...

WALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today ...

1 month ago - GlobeNewsWire

Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors

WALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today...

1 month ago - GlobeNewsWire

Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Int...

WALTHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Invivyd, (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today annou...

1 month ago - GlobeNewsWire

Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022

WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Invivyd, (Nasdaq: IVVD), formerly Adagio Therapeutics (Nasdaq: ADGI), a clinical-stage biopharmaceutical company on a mission to protect humanity from s...

1 month ago - GlobeNewsWire

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews David Hering CEO, Invivyd Inc.

NEW YORK, NY / ACCESSWIRE / October 3, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued ...

2 months ago - Accesswire

Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancem...

WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Invivyd, (Nasdaq: IVVD beginning September 13), formerly Adagio Therapeutics (Nasdaq: ADGI), a clinical-stage biopharmaceutical company on a mission to...

2 months ago - GlobeNewsWire

Adagio Therapeutics Announces Corporate Name Change to Invivyd

WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, (Nasdaq: ADGI), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory disease...

2 months ago - GlobeNewsWire

Adagio Therapeutics to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of dif...

2 months ago - GlobeNewsWire

Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

$475 Million in Cash and Cash Equivalents to Support Operating Runway into Second Quarter of 2024

3 months ago - GlobeNewsWire

Mithril Capital's Ajay Royan Sends Letter Thanking Adagio Therapeutics Shareholders for Support of Successful Proxy C...

AUSTIN, Texas--(BUSINESS WIRE)--Mithril Capital Management LLC (“Mithril”), a founding investor in and the leader of a consortium of investors that represented approximately 49% of the outstanding share...

4 months ago - Business Wire

Adagio Announces David Hering Named Permanent Chief Executive Officer and Director

WALTHAM, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of anti...

5 months ago - GlobeNewsWire

(ADGI) News: Did You Lose Money on Your Adagio Therapeutics Investment? Stock Price has Plummeted Since IPO - Contact...

San Diego, California--(Newsfile Corp. - July 3, 2022) - Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Adagio Therapeutics, Inc. ("Adagio " or the "Com...

5 months ago - Newsfile Corp

Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors

Marc Elia Named Chair of the Board of Directors Marc Elia Named Chair of the Board of Directors

5 months ago - GlobeNewsWire

Adagio Therapeutics Reports First Quarter 2022 Financial Results

$532.2 Million in Total Cash at Quarter End; Strong Balance Sheet Expected to Support Operations into Second Half of 2024

6 months ago - GlobeNewsWire

Adagio Pauses FDA Emergency Use Request For Its COVID-19 Therapy

Adagio Therapeutics Inc (NASDAQ: ADGI) provided an update on the anticipated timing for its Emergency Use Authorization (EUA) request for adintrevimab (ADG20) for the prevention and treatment of COVID-1...

7 months ago - Benzinga

Adagio Therapeutics Provides Update on Timing of Adintrevimab EUA Request

WALTHAM, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ant...

7 months ago - GlobeNewsWire

Adagio's (ADGI) COVID-19 Antibody Meets Goals in Studies

The stock price of Adagio (ADGI) surge after it reports positive preliminary data from the phase II/III studies, which evaluate its monoclonal antibody for the prevention and treatment of COVID-19.

8 months ago - Zacks Investment Research

Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?

Penny stocks are a hot subject today with several of the top companies in the market seeing major gains on Wednesday and we know why! The post Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GER...

Other symbols: DRCTGERNNAOVSNOAVYNT
8 months ago - InvestorPlace

Why Is Adagio Therapeutics (ADGI) Stock Up Today?

Adagio recently announced that lab data has proven the effectiveness of its antibody treatment. ADGI stock is up more than 40% on the news.

8 months ago - InvestorPlace

Adagio's COVID-19 Antibody Meets Primary Goals Across Pre & Post-Exposure Prophylaxis, Treatment

Adagio Therapeutics Inc's (NASDAQ: ADGI) Phase 2/3 trials evaluating 300 mg adintrevimab (ADG20) as pre-and-post-exposure prophylaxis (EVADE) and treatment (STAMP) for COVID-19 have met its primary endp...

8 months ago - Benzinga

Why Adagio Therapeutics Stock Is Soaring Today.

Investors are reacting to better than expected clinical trial results for its COVID-19 treatment candidate.

8 months ago - The Motley Fool

Why Adagio Therapeutics Stock Is Soaring Today

Adagio Therapeutics Inc (NASDAQ: ADGI) is trading higher Wednesday after the company announced its investigational drug adintrevimab (ADG20) was the first monoclonal antibody to meet primary endpoints w...

8 months ago - Benzinga